189 related articles for article (PubMed ID: 29959787)
21. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers.
Ino H; Endo A; Wakamatsu A; Ogura H; Numachi Y; Kendrick S
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):70-77. PubMed ID: 29870578
[TBL] [Abstract][Full Text] [Related]
22. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
23. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.
Graffner H; Gillberg PG; Rikner L; Marschall HU
Aliment Pharmacol Ther; 2016 Jan; 43(2):303-10. PubMed ID: 26527417
[TBL] [Abstract][Full Text] [Related]
24. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Palmer M; Jennings L; Silberg DG; Bliss C; Martin P
BMC Pharmacol Toxicol; 2018 Mar; 19(1):10. PubMed ID: 29548345
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.
Mosińska P; Fichna J; Storr M
World J Gastroenterol; 2015 Jun; 21(24):7436-42. PubMed ID: 26139989
[TBL] [Abstract][Full Text] [Related]
26. Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM.
Yoshinobu S; Hasuzawa N; Nagayama A; Iwata S; Yasuda J; Tokubuchi R; Kabashima M; Gobaru M; Hara K; Murotani K; Moriyama Y; Ashida K; Nomura M
Clin Ther; 2022 Oct; 44(10):1418-1426. PubMed ID: 36117045
[TBL] [Abstract][Full Text] [Related]
27. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
28. Review article: Elobixibat: a novel treatment for chronic constipation.
Khanna L; Camilleri M
Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
[TBL] [Abstract][Full Text] [Related]
29. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice.
Yamauchi R; Takedatsu H; Yokoyama K; Yamauchi E; Kawashima M; Nagata T; Uchida Y; Kitaguchi T; Higashi T; Fukuda H; Tsuchiya N; Takata K; Tanaka T; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
Hepatol Int; 2021 Apr; 15(2):392-404. PubMed ID: 33398776
[TBL] [Abstract][Full Text] [Related]
30. Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.
Hishida Y; Nagai Y; Tsukiyama H; Nakamura Y; Nakagawa T; Ishizaki S; Tanaka Y; Sone M
Adv Ther; 2022 Sep; 39(9):4205-4217. PubMed ID: 35867276
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
[TBL] [Abstract][Full Text] [Related]
32. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Ooba N; Takahashi Y; Nagamura M; Takahashi M; Ushida M; Kawakami E; Kimura M; Sato T; Tokuyoshi J; Miyazaki C; Shimada M
Expert Opin Drug Saf; 2021 Dec; 20(12):1553-1558. PubMed ID: 34281471
[TBL] [Abstract][Full Text] [Related]
33. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM; Vandeplassche L; Kerstens R; Ausma J
Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
[TBL] [Abstract][Full Text] [Related]
34. Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.
Tanaka K; Kessoku T; Yamamoto A; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Kato T; Arimoto J; Fuyuki A; Sakai E; Higurashi T; Chiba H; Hosono K; Yoneda M; Iwasaki T; Kurihashi T; Nakatogawa M; Suzuki A; Taguri M; Oyamada S; Ariyoshi K; Kobayashi N; Ichikawa Y; Nakajima A
BMJ Open; 2022 May; 12(5):e060704. PubMed ID: 35636802
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance.
Nakajima A; Fujimaki M; Arai Y; Emori K
J Neurogastroenterol Motil; 2022 Jul; 28(3):431-441. PubMed ID: 35799237
[TBL] [Abstract][Full Text] [Related]
36. Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure.
Fujisue K; Ito M; Matsuzawa Y; Arima Y; Takashio S; Sueta D; Araki S; Hanatani S; Yamanaga K; Yamamoto M; Kaneko S; Yamamoto E; Matsushita K; Soejima H; Tsujita K
Circ Rep; 2024 Mar; 6(3):55-63. PubMed ID: 38464992
[No Abstract] [Full Text] [Related]
37. New pharmacological treatment options for chronic constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
[TBL] [Abstract][Full Text] [Related]
39. Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review.
Odaka T; Tominaga K
Curr Ther Res Clin Exp; 2020; 93():100616. PubMed ID: 33320111
[TBL] [Abstract][Full Text] [Related]
40. Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.
Manabe N; Umeyama M; Ishizaki S; Ota T; Kuratani S; Katsumata R; Fujita M; Haruma K; Camilleri M
BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 37993269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
